USFDA17 Apr 2025, 08:06 pm
Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur
AI Summary
Global pharma major Lupin Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for drug-medical device combination products at its injectable facility in Nagpur, India. The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024. Nilesh Gupta, Managing Director, Lupin expressed delight and reiterated the company's commitment to producing complex generic and essential products that address unmet needs.
Key Highlights
- Lupin Limited receives EIR from US FDA for drug-medical device combination products at its Nagpur injectable facility.
- The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024.
- Lupin remains committed to producing complex generic and essential products that address unmet needs.